PuREC(PCTBP)

Focus: PuREC is a public biotech company founded in 2021 specializing in regenerative cell therapy using purified Mesenchymal Stem Cells. The company is early-stage with no approved products and minimal clinical pipeline activity.

Cell Therapy Gene Therapy

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About PuREC

AI assessmentNot Hiring

No open roles listed right now. Follow PuREC to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2021

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for PuREC

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build from the ground up in regenerative medicine, a high-growth therapeutic area with significant unmet needs
Public company status provides equity liquidity and access to capital markets for funding R&D expansion
Focused technology platform in MSC-based therapies offers clear technical differentiation in a nascent field

Watch Out For

Zero active clinical trials and no marketed products indicate extremely early-stage risk with uncertain path to revenue
Cumulative net losses of $186M over two years with only $73M cash on hand suggests runway concerns without major funding or partnership
No active job openings and minimal headcount data suggest limited hiring momentum and organizational uncertainty

Generated by Claude from PuREC's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Revenue

R&D Spend

$7M52%

Net Income

-$102M

Cash

$73M

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo